Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-man (FIM) study of the Stentys bifurcation stent--30 days results.
Verheye S, Grube E, Ramcharitar S, Schofer JJ, Witzenbichler B, Kovac J, Hauptmann KE, Agostoni P, Wiemer M, Lefèvre T, Serruys PW, van Geuns RJ. Verheye S, et al. Among authors: schofer jj. EuroIntervention. 2009 Mar;4(5):566-71. doi: 10.4244/eijv4i5a96. EuroIntervention. 2009. PMID: 19378675 Clinical Trial.
Six-month clinical and angiographic results of the STENTYS® self-apposing stent in bifurcation lesions.
Verheye S, Ramcharitar S, Grube E, Schofer JJ, Witzenbichler B, Kovac J, Hauptmann KE, Agostoni P, Wiemer M, Lefèvre T, Spaargaren R, Serruys PW, García-García HM, van Geuns RJ. Verheye S, et al. Among authors: schofer jj. EuroIntervention. 2011 Sep;7(5):580-7. doi: 10.4244/EIJV7I5A94. EuroIntervention. 2011. PMID: 21930462 Free article. Clinical Trial.
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. Serruys PW, et al. EuroIntervention. 2010 Jun;6(2):195-205. EuroIntervention. 2010. PMID: 20562069 Clinical Trial.
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial.
Verheye S, Agostoni P, Dawkins KD, Dens J, Rutsch W, Carrie D, Schofer J, Lotan C, Dubois CL, Cohen SA, Fitzgerald PJ, Lansky AJ. Verheye S, et al. JACC Cardiovasc Interv. 2009 Mar;2(3):205-14. doi: 10.1016/j.jcin.2008.12.011. JACC Cardiovasc Interv. 2009. PMID: 19463427 Free article. Clinical Trial.
Direct Flow Medical valve.
Bijuklic K, Tübler T, Low RI, Grube E, Schofer J. Bijuklic K, et al. EuroIntervention. 2012 Sep;8 Suppl Q:Q75-8. doi: 10.4244/EIJV8SQA13. EuroIntervention. 2012. PMID: 22995116 Free article.
Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Abizaid A, Ormiston JA, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Macours N, Qureshi AC, Spaulding C; NEVO ResElution-I Investigators. Abizaid A, et al. EuroIntervention. 2013 Oct;9(6):721-9. doi: 10.4244/EIJV9I6A116. EuroIntervention. 2013. PMID: 23518218 Free article.
Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR Jr, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, Verheye S. Abizaid A, et al. JACC Cardiovasc Interv. 2016 Mar 28;9(6):565-74. doi: 10.1016/j.jcin.2015.12.004. JACC Cardiovasc Interv. 2016. PMID: 27013155 Free article. Clinical Trial.
248 results